VRTXON

Vertex Pharmaceuticals Incorporated, a biotechnology company, engages in developing and commercializing therapies for treating cystic fibrosis. The company markets SYMDEKO/SYMKEVI, ORKAMBI, and KALYDECO to treat patients with cystic fibrosis who have specific mutations in their cystic fibrosis transmembrane conductance regulator gene; and TRIKAFTA for the treatment of patients with CF 6 years of age or older who have at least one F508del mutation.

Ime in priimekVRTXON

UvrstitevNo.3684

Tržna kapitalizacija$0.00

Popolnoma razredčena tržna kapitalizacija$0.00

Tržni delež%

Volumen trgovanja/tržna kapitalizacija (24h)78,245,820.91%

Razpoložljivi obtok0.92556582

Največja ponudba0

Skupna ponudba0.92556582

Hitrost kroženja%

Datum izdaje--

Cena, po kateri je bilo sredstvo prvič izdano--

Najvišja vrednost vseh časov466.35223147502205,2026-03-26

Najnižja cena426.5493484981209,2026-04-07

Javna veriga blokovETH

UvodVertex Pharmaceuticals Incorporated, a biotechnology company, engages in developing and commercializing therapies for treating cystic fibrosis. The company markets SYMDEKO/SYMKEVI, ORKAMBI, and KALYDECO to treat patients with cystic fibrosis who have specific mutations in their cystic fibrosis transmembrane conductance regulator gene; and TRIKAFTA for the treatment of patients with CF 6 years of age or older who have at least one F508del mutation.

Panoga

Družbeni mediji

• Uradna spletna stran
• Raziskovalec blokov

etfindex:mc_etfindex_sourceOmejitev odgovornosti: Podatke zagotavlja cmc in se ne smejo obravnavati kot naložbeni nasveti.